HLVX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 0.06%, SMA50 0.02%, SMA200 9.04%). The stock’s 14-day RSI is 51.29 (neutral), while the ATR of 0.03 points to moderate volatility. The stock remains hovering near 52-week lows, trading -3.69% below its high and over 55.97% above its low.

HilleVax, Inc. generated EPS of -$1.43 over the past year. Five-year average earnings growth is -166.47%. The latest quarter delivered EPS of -$0.52. The next quarter is forecast at $nan. Next year's EPS is expected at -$5.84. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $2.00 to $2.00. The high target offers -4.31% upside. The low target suggests -4.31% downside. The mean target is $2.00. This offers -4.31% upside. HilleVax, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 246.67%. The prior quarter beat by -21.43%. Over the last six quarters, Apple has recorded several small beats. These include 13.7% in August 08, 2024.

HilleVax, Inc. has 50.13 million shares outstanding. The public float is 27.41 million shares, elevated short interest at 2.10% of float. This equals 444.02 thousand shares. The short ratio is 3.06 days. Institutional investors hold 84.96% of the float. Insiders own 17.09%. Frazier Life Sciences X, L.P. holds 8.54 million shares, Heron Patrick J has 8.54 million shares and HERSHBERG ROBERT has 1.10 million shares.

HilleVax, Inc. (NASDAQ:HLVX) shares are flat 0.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows HilleVax, Inc. trading at a premium to the broader market with a P/E of -1.47. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $8.75, suggesting 318.66% upside.

Our AI price prediction model suggests that HilleVax, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected rise of 2776.56%, reaching $60.12 by December 17, 2025, with a range of $58.81 to $63.88. 1-Year Outlook: Projected gain of 117.7%, with price at $4.55 by September 18, 2026, within a range of $0.00 to $4.85.

HilleVax, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.64. This means the shares are trading below this model’s fair value.

HilleVax, Inc. (NASDAQ:HLVX) closed at $2.09 USD, losing -$0.01 (-0.48%) from the previous close of $2.10. The stock is currently within 5% of its 52-week high $1.34 and $2.17. With a market capitalization of about $104.76 million, HilleVax, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.77). Key stats such as the average daily volume over the past year has been around 718.71 thousand shares, trading with heavier-than-usual volume. Headquartered in Boston, MA, HilleVax, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert M. Hershberg, the company employs approximately 14 people and listed since April 29, 2022. HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines.

HilleVax, Inc. trades at a P/E ratio of -1.47, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.71 suggesting the stock is closer to book value. The P/FCF stands at -1.71, also below market averages.